StageZero Life Sciences Ltd. (SZLSF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2022 | -403.74 Thousand USD | -134.29% |
| 2021 | 1.17 Million USD | 69.29% |
| 2020 | 695.55 Thousand USD | 172.38% |
| 2019 | -960.91 Thousand USD | 10.97% |
| 2018 | -1.07 Million USD | -8.72% |
| 2017 | -992.7 Thousand USD | -139.38% |
| 2016 | -414.7 Thousand USD | -227.28% |
| 2015 | 325.8 Thousand USD | -84.58% |
| 2014 | 2.11 Million USD | 245.64% |
| 2013 | -1.45 Million USD | 12.35% |
| 2012 | -1.65 Million USD | -1776.18% |
| 2011 | 98.73 Thousand USD | -48.97% |
| 2010 | 193.47 Thousand USD | -82.32% |
| 2009 | 1.09 Million USD | -6.34% |
| 2008 | 1.16 Million USD | -46.62% |
| 2007 | 2.18 Million USD | -22.29% |
| 2006 | 2.81 Million USD | -38.72% |
| 2005 | 4.59 Million USD | 148.15% |
| 2004 | 1.85 Million USD | -36.24% |
| 2003 | 2.9 Million USD | 1815.64% |
| 2002 | 151.64 Thousand USD | 6.94% |
| 2001 | 141.8 Thousand USD | 0.0% |
| 2000 | 141.8 Thousand USD | 108.81% |
| 1999 | 67.9 Thousand USD | 10430717.06% |
| 1998 | 0.65 USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 281 Thousand USD | 0.0% |
| 2024 Q2 | 7818.00 USD | -97.22% |
| 2023 Q3 | 168.41 Thousand USD | 38.55% |
| 2023 Q1 | 136.08 Thousand USD | 132.74% |
| 2023 Q2 | 121.55 Thousand USD | -10.68% |
| 2022 Q1 | -40.27 Thousand USD | -5.87% |
| 2022 Q3 | 138.32 Thousand USD | 260.68% |
| 2022 Q2 | -86.08 Thousand USD | -113.72% |
| 2022 FY | -403.74 Thousand USD | -134.29% |
| 2022 Q4 | -415.7 Thousand USD | -400.53% |
| 2021 Q1 | 1.54 Million USD | 181.54% |
| 2021 Q3 | -123.02 Thousand USD | 40.05% |
| 2021 Q4 | -38.04 Thousand USD | 69.07% |
| 2021 Q2 | -205.21 Thousand USD | -113.29% |
| 2021 FY | 1.17 Million USD | 69.29% |
| 2020 Q3 | 490.65 Thousand USD | 466.94% |
| 2020 Q4 | 548.33 Thousand USD | 11.76% |
| 2020 FY | 695.55 Thousand USD | 172.38% |
| 2020 Q1 | -166.3 Thousand USD | 23.39% |
| 2020 Q2 | -133.71 Thousand USD | 19.6% |
| 2019 FY | -960.91 Thousand USD | 10.97% |
| 2019 Q1 | -231.75 Thousand USD | 16.75% |
| 2019 Q4 | -217.08 Thousand USD | 14.12% |
| 2019 Q3 | -252.78 Thousand USD | 2.51% |
| 2019 Q2 | -259.29 Thousand USD | -11.89% |
| 2018 Q4 | -278.37 Thousand USD | -37.42% |
| 2018 FY | -1.07 Million USD | -8.72% |
| 2018 Q1 | -296.16 Thousand USD | -14.54% |
| 2018 Q2 | -302.21 Thousand USD | -2.04% |
| 2018 Q3 | -202.57 Thousand USD | 32.97% |
| 2017 Q1 | -201.7 Thousand USD | -710.73% |
| 2017 FY | -992.7 Thousand USD | -139.38% |
| 2017 Q3 | -102.04 Thousand USD | 76.29% |
| 2017 Q4 | -258.57 Thousand USD | -153.4% |
| 2017 Q2 | -430.39 Thousand USD | -113.38% |
| 2016 FY | -414.7 Thousand USD | -227.28% |
| 2016 Q1 | -65.33 Thousand USD | 0.0% |
| 2016 Q4 | 33.02 Thousand USD | 110.1% |
| 2016 Q3 | -326.82 Thousand USD | -488.22% |
| 2016 Q2 | -55.56 Thousand USD | 14.96% |
| 2015 Q1 | 623.72 Thousand USD | 14.83% |
| 2015 Q2 | 585.25 Thousand USD | -6.17% |
| 2015 Q3 | -903.77 Thousand USD | -254.42% |
| 2015 FY | 325.8 Thousand USD | -84.58% |
| 2015 Q4 | - USD | 100.0% |
| 2014 FY | 2.11 Million USD | 245.64% |
| 2014 Q4 | 543.19 Thousand USD | -45.32% |
| 2014 Q3 | 993.42 Thousand USD | 140.28% |
| 2014 Q2 | 413.45 Thousand USD | 126.42% |
| 2014 Q1 | 182.6 Thousand USD | 365.32% |
| 2013 FY | -1.45 Million USD | 12.35% |
| 2013 Q4 | -68.82 Thousand USD | 84.4% |
| 2013 Q3 | -441.13 Thousand USD | 17.37% |
| 2013 Q2 | -533.86 Thousand USD | -19.5% |
| 2013 Q1 | -446.76 Thousand USD | -3.71% |
| 2012 Q2 | 55.35 Thousand USD | 752.71% |
| 2012 Q4 | -430.77 Thousand USD | -7.69% |
| 2012 Q1 | 6491.87 USD | 50.07% |
| 2012 Q3 | -400 Thousand USD | -822.6% |
| 2012 FY | -1.65 Million USD | -1776.18% |
| 2011 FY | 98.73 Thousand USD | -48.97% |
| 2011 Q1 | 45.45 Thousand USD | 385.66% |
| 2011 Q2 | 10.1 Thousand USD | -77.76% |
| 2011 Q3 | 183.07 Thousand USD | 1711.17% |
| 2011 Q4 | 4325.75 USD | -97.64% |
| 2010 Q3 | 161.38 Thousand USD | 793.3% |
| 2010 Q4 | 9359.06 USD | -94.2% |
| 2010 Q2 | 18.06 Thousand USD | 316.95% |
| 2010 Q1 | 4332.94 USD | -98.93% |
| 2010 FY | 193.47 Thousand USD | -82.32% |
| 2009 Q4 | 406.28 Thousand USD | 19.65% |
| 2009 Q2 | 97.54 Thousand USD | -52.48% |
| 2009 Q1 | 205.28 Thousand USD | -38.19% |
| 2009 Q3 | 339.56 Thousand USD | 248.12% |
| 2009 FY | 1.09 Million USD | -6.34% |
| 2008 Q4 | 332.09 Thousand USD | 16.2% |
| 2008 Q1 | 285.9 Thousand USD | -44.01% |
| 2008 Q2 | 283.39 Thousand USD | -0.88% |
| 2008 Q3 | 285.79 Thousand USD | 0.85% |
| 2008 FY | 1.16 Million USD | -46.62% |
| 2007 FY | 2.18 Million USD | -22.29% |
| 2007 Q1 | 1.44 Million USD | 206.77% |
| 2007 Q2 | 507.23 Thousand USD | -64.88% |
| 2007 Q3 | 190.53 Thousand USD | -62.44% |
| 2007 Q4 | 510.62 Thousand USD | 168.0% |
| 2006 Q4 | 470.82 Thousand USD | -40.14% |
| 2006 Q3 | 786.56 Thousand USD | 0.39% |
| 2006 Q2 | 783.53 Thousand USD | 5.21% |
| 2006 Q1 | 744.74 Thousand USD | -58.29% |
| 2006 FY | 2.81 Million USD | -38.72% |
| 2005 Q2 | 1.22 Million USD | 68.48% |
| 2005 Q3 | 766.68 Thousand USD | -37.32% |
| 2005 FY | 4.59 Million USD | 148.15% |
| 2005 Q4 | 1.78 Million USD | 132.91% |
| 2005 Q1 | 726 Thousand USD | -45.16% |
| 2004 FY | 1.85 Million USD | -36.24% |
| 2004 Q2 | 167.4 Thousand USD | 1.87% |
| 2004 Q4 | 1.32 Million USD | 632.12% |
| 2004 Q1 | 164.33 Thousand USD | -86.91% |
| 2004 Q3 | 180.81 Thousand USD | 8.01% |
| 2003 Q2 | 185.61 Thousand USD | -84.41% |
| 2003 Q3 | 172.86 Thousand USD | -6.87% |
| 2003 Q4 | 1.25 Million USD | 625.99% |
| 2003 Q1 | 1.19 Million USD | 1148.56% |
| 2003 FY | 2.9 Million USD | 1815.64% |
| 2002 FY | 151.64 Thousand USD | 6.94% |
| 2002 Q4 | 95.34 Thousand USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q3 | - USD | 0.0% |
| 2001 Q1 | 42.83 Thousand USD | 28.72% |
| 2001 FY | 141.8 Thousand USD | 0.0% |
| 2001 Q4 | - USD | -100.0% |
| 2001 Q3 | 0.65 USD | -100.0% |
| 2001 Q2 | 46.59 Thousand USD | 8.78% |
| 2000 Q4 | 33.27 Thousand USD | 66.87% |
| 2000 Q3 | 19.94 Thousand USD | 0.0% |
| 2000 Q1 | 0.69 USD | -100.0% |
| 2000 FY | 141.8 Thousand USD | 108.81% |
| 1999 FY | 67.9 Thousand USD | 10430717.06% |
| 1999 Q4 | 67.9 Thousand USD | 10149235.37% |
| 1999 Q1 | 0.66 USD | 0.0% |
| 1999 Q3 | 0.67 USD | -1.34% |
| 1999 Q2 | 0.68 USD | 2.31% |
| 1998 FY | 0.65 USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| American Bio Medica Corporation | -193 Thousand USD | -109.195% |
| Arrayit Corporation | 2.57 Million USD | 115.679% |
| Atlantic International Corp. | -154.23 Thousand USD | -161.776% |
| Biocept, Inc. | -2.58 Million USD | 84.363% |
| Bioqual, Inc. | 7.42 Million USD | 105.435% |
| CardioGenics Holdings Inc | - USD | Infinity% |
| DermTech, Inc. | 276 Thousand USD | 246.285% |
| Global WholeHealth Partners Corporation | - USD | Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 6.73 Billion USD | 100.006% |
| HTG Molecular Diagnostics, Inc. | 1.79 Million USD | 122.504% |
| iMD Companies, Inc. | -23.63 Thousand USD | -1608.114% |
| IDenta Corp. | 662.97 Thousand USD | 160.899% |
| Interpace Biosciences, Inc. | 23.04 Million USD | 101.752% |
| Integrative Health Technologies, Inc. | 77.57 Thousand USD | 620.487% |
| InVitro International | 635.98 Thousand USD | 163.484% |
| Lumos Diagnostics Holdings Limited | 6.56 Million USD | 106.152% |
| Many Bright Ideas Technologies Inc. | - USD | Infinity% |
| Medical Imaging Corp. | 1.09 Million USD | 136.95% |
| NovelStem International Corp. | 12 Thousand USD | 3464.558% |
| Optigenex Inc. | -102.96 Thousand USD | -292.117% |
| PharmChem, Inc. | 3.9 Million USD | 110.341% |
| Proteome Sciences plc | 2.09 Million USD | 119.257% |
| Response Genetics, Inc | 3.94 Million USD | 110.242% |
| Rennova Health, Inc. | 6.26 Million USD | 106.441% |
| RushNet, Inc. | 1.1 Million USD | 136.551% |
| ScreenPro Security Inc. | 856.57 Thousand USD | 147.135% |
| Stella Diagnostics Inc. | - USD | Infinity% |
| Todos Medical Ltd. | 4.31 Million USD | 109.368% |